Discounted Cash Flow (DCF) Analysis Unlevered

Apellis Pharmaceuticals, Inc. (APLS)

$68.47

+0.88 (+1.30%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 68.47 | undervalue

Operating Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 68.47
Beta 0.930
Diluted Shares Outstanding 75.16
Cost of Debt
Tax Rate -0.10
After-tax Cost of Debt 28.95%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.675
Total Debt 112.71
Total Equity 5,146.41
Total Capital 5,259.12
Debt Weighting 2.14
Equity Weighting 97.86
Wacc

Build Up Free Cash

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%-1.68%-0.54%-0.05%-0.10%-0.47%-0.47%-0.47%-0.47%-0.47%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure --1.69-5.42-1.10-1.52-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 9.11
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -439.09
Equity Value -
Shares Outstanding 75.16
Equity Value Per Share -